Readnour Robin Shane

Director Robin Shane purchases 60,000 shares in 6 transactions (Dec 6–10) at blended average $1.45; holdings now 652,573 shares (+10.1%).

Robin Shane, a Director at AN2 Therapeutics, completed 6 separate purchases totaling 60,000 shares for $86,708.01 over a 5-day window (Dec 6–10, 2024) at prices ranging from $1.43 to $1.49. This represents a 10.1% increase to his post-transaction holdings of 652,573 shares. The transaction occurred while the stock trades at $1.51 (current price), still down 93.0% from its 52-week high of $21.53, though it has risen 37.3% over the past 30 days and 45.2% over 90 days. The company reported a net loss of $12,747,000.00 over its most recent fiscal year with a market cap of $45,117,123.90. His prior trading activity at ANTX shows 5 recent buys in late November, though none of those outcomes are yet measurable at the 90-day mark.

Director Readnour Robin Shane bought 75,000 shares (75.0K) at $1.41–$1.42 in 4 transactions; stock -93.6% from 52-week high; unprofitable company; cluster buy pattern with 2 other insiders.

Director Readnour Robin Shane executed 4 separate purchases totaling 75,000 shares for $105,685.00 on 2024-11-26 and 2024-11-27, raising his holdings from 547,573 to 622,573 shares (+13.7%). The filing occurs as the stock trades at $1.37, down -93.6% from its 52-week high of $21.53, despite a +24.6% 30-day rebound. The company reported negative net income of $-12,747,000.00 on a market cap of $40,934,079.30, indicating material unprofitability. A cluster pattern shows 2 other insiders also bought within the past 14 days, concurrent with Shane's accumulation. This sequence of open-market purchases at depressed absolute prices warrants scrutiny given the company's unprofitable status and the stock's severe drawdown from recent highs.

Director Robin Shane buys 200,000 shares for $213,127.50 at AN2 Therapeutics; cluster buy pattern with 2 other insiders in past 14 days.

Robin Shane, a director at AN2 Therapeutics, executed 4 separate purchases totaling 200,000 shares for $213,127.50 (blended average $1.07) across November 19-20, 2024, expanding holdings from 314.8K to 514.8K shares (+63.5%). This accumulation occurs amid a cluster buy pattern, with 2 other insiders also purchasing within the past 14 days. The company remains unprofitable with full-year net income of $-12.7M and a market cap of $36.8M, while the stock trades 94.3% below its 52-week high of $21.53 yet up 13.9% over the past 30 days. The concurrent purchases by multiple insiders at depressed valuations warrant investor attention to whether the board perceives fundamental value below current market pricing.